Peripheral immune markers and choroid plexus volumes as predictors of change in depressive symptoms: Insights from the EMBARC study.
PsychoneuroendocrinologyJul 14, 2026 (epub)
Clinical ResearchPsychiatry
Emine Rabia Ayvaci, Bharathi S Gadad, Russell Toll et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial examined the predictive value of baseline immune markers and choroid plexus (ChP) volumes on changes in depressive symptoms among 222 adults with Major Depressive Disorder (MDD) over 8 weeks. The study found that higher levels of certain cytokines and chemokines were associated with less improvement in depressive symptoms, with an estimate of 1.211 (p = 0.018).
Key findings
- Higher levels of IL-6, TNF-α, and IL-1β were linked to greater depression severity at baseline.
- Higher immune marker levels predicted less improvement in depressive symptoms at 8 weeks (estimate = 1.211, p = 0.018).
- Right ChP volume model showed an estimate of 1.034 (p = 0.005) for immune markers predicting symptom change.
- Left ChP volume model indicated an estimate of 0.993 (p = 0.007) for immune markers predicting symptom change.
Why it matters
Understanding the relationship between immune markers and changes in depressive symptoms can help clinicians identify patients at risk for poor treatment response, potentially guiding more personalized therapeutic approaches in managing Major Depressive Disorder.